In a report published Friday, Citigroup reiterated its Buy rating on Celgene Corporation CELG, and raised its price target from $93.00 to $114.00.
Citigroup noted, “Coming out of Q4:12 earnings Celgene's business continues to perform well and we're bullish on the 2013 outlook and see many ways for Celgene to meet/beat ests. We believe Revlimid sales will continue to grow in 2013 and upside to revs and EPS guidance will be bolstered by: 1) strong Abraxane sales given the recent positive pancreatic data; 2) recent Abraxane NSCLC approval; 3) delayed generic Vidaza; and 4) the remaining ~$1.8B in stock buybacks. Celgene is our top idea for lg cap biotech and we expect positive data from the MM-020 study in March/April and that should drive both upwards revs/EPS revisions in 2014 and beyond and multiple expansion. In addition, upcoming apremilast Ph 3 data in psoriasis in Q1:13 and regulatory filing this year should further drive multiple expansion.”
Celgene Corporation closed on Thursday at $97.49.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in